At the time of writing, Blueprint Medicines Corp [BPMC] stock is trading at $127.85, down -0.04%. An important factor to consider is whether the stock is rising or falling in short-term value. The BPMC shares have gain 26.15% over the last week, with a monthly amount glided 28.11%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Blueprint Medicines Corp [NASDAQ: BPMC] stock has seen the most recent analyst activity on June 02, 2025, when Wedbush downgraded its rating to a Neutral but kept the price target unchanged to $129 for it. On March 18, 2025, Wolfe Research initiated with a Outperform rating. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $135 on March 17, 2025. Scotiabank initiated its recommendation with a Sector Outperform and recommended $150 as its price target on March 07, 2025. JP Morgan started tracking with a Overweight rating for this stock on November 14, 2024, and assigned it a price target of $126. In a note dated October 24, 2024, UBS initiated an Neutral rating and provided a target price of $88 on this stock.
For the past year, the stock price of Blueprint Medicines Corp fluctuated between $73.04 and $128.24. Currently, Wall Street analysts expect the stock to reach $141 within the next 12 months. Blueprint Medicines Corp [NASDAQ: BPMC] shares were valued at $127.85 at the most recent close of the market. An investor can expect a potential return of 10.29% based on the average BPMC price forecast.
Analyzing the BPMC fundamentals
According to Blueprint Medicines Corp [NASDAQ:BPMC], the company’s sales were 562.12M for trailing twelve months, which represents an 55.45% jump. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -0.31%, Pretax Profit Margin comes in at -0.27%, and Net Profit Margin reading is -0.28%. To continue investigating profitability, this company’s Return on Assets is posted at -0.13, Equity is -0.49 and Total Capital is -0.18. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.36.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 127.72 points at the first support level, and at 127.60 for the second support level. However, for the 1st resistance point, the stock is sitting at 128.02, and for the 2nd resistance point, it is at 128.20.
Ratios To Look Out For
It is important to note that Blueprint Medicines Corp [NASDAQ:BPMC] has a current ratio of 2.80. On the other hand, the Quick Ratio is 2.75, and the Cash Ratio is 0.49. Considering the valuation of this stock, the price to sales ratio is 14.69, the price to book ratio is 24.13.
Transactions by insiders
Recent insider trading involved Carter Percy H., CHIEF SCIENTIFIC OFFICER, that happened on Jun 03 ’25 when 2659.0 shares were sold. Director, Albers Jeffrey W. completed a deal on May 27 ’25 to sell 5000.0 shares. Meanwhile, Director Albers Jeffrey W. bought 5000.0 shares on May 27 ’25.
